Herpes Viruses Explained — The 9 Viruses That Stay With You for Life

Nine herpesviruses infect people, and every one of them is for keeps. After the first infection, the virus does not leave; it retreats into nerve cells or immune cells and waits, sometimes for decades. The World Health Organization estimates that 64% of people under 50 carry herpes simplex virus type 1 alone, and Epstein-Barr virus infects about 95% of adults. This article explains how the family's hide-and-wait strategy works, what each of the nine viruses causes, and why vaccines and cures have been so hard to build.

Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects current research but every person's situation differs.

What are the nine human herpesviruses?

Herpesviruses are large viruses whose genetic material is double-stranded DNA wrapped in a protein shell and an outer lipid envelope. The family that contains them, Herpesviridae, is split by the International Committee on Taxonomy of Viruses (ICTV) into three subfamilies called alpha, beta, and gamma (ICTV chapter listing). Species in the family infect mammals, birds, and reptiles, and many have been named.

Nine of them infect humans. Eight carry a number from HHV-1 to HHV-8 (HHV stands for human herpesvirus), and the sixth is split into two close relatives, 6A and 6B, which gives nine species in total.

Number	Short name	Common name	Subfamily	Best-known diseases
HHV-1	HSV-1	Herpes simplex virus 1	Alpha	Cold sores, genital herpes
HHV-2	HSV-2	Herpes simplex virus 2	Alpha	Genital herpes
HHV-3	VZV	Varicella-zoster virus	Alpha	Chickenpox, shingles
HHV-4	EBV	Epstein-Barr virus	Gamma	Mononucleosis, several cancers
HHV-5	CMV	Cytomegalovirus	Beta	Usually silent; congenital infection, transplant disease
HHV-6A and 6B	HHV-6	Roseolovirus	Beta	Roseola in infants
HHV-7	HHV-7	Roseolovirus	Beta	Roseola, usually mild
HHV-8	KSHV	Kaposi's sarcoma-associated herpesvirus	Gamma	Kaposi's sarcoma, two rare lymphoproliferative diseases

The subfamily labels carry real biology. Alpha viruses tend to grow fast and settle in nerve cells, beta viruses grow slowly and favor immune and gland cells, and gamma viruses live mainly in lymphocytes, the white blood cells that make antibodies and coordinate immune responses.

For a wider view of how any virus gets into a cell and copies itself, see our explainer on how viruses work from infection to replication.

How does a herpesvirus stay for life?

Think of a herpesvirus as a sleeper agent rather than an invader. Most viruses attack, replicate wildly, and get cleared or kill the host within weeks. Herpesviruses run two programs instead: a loud one that makes new virus particles and a silent one that makes almost nothing.

The loud program is called the lytic cycle (from the Greek for "loosening," because the infected cell eventually bursts). The silent program is latency. A cell in latency still holds the full viral genome, but only a handful of viral genes are switched on, so there is very little for immune cells to recognize. Picture a seed in a drawer: alive, intact, invisible, and ready to sprout when conditions change.

Where each virus hides

Each virus has a preferred hiding place, and the choice explains much of the disease pattern.

• HSV-1, HSV-2, and VZV settle in sensory neurons, the nerve cells that carry touch and pain signals from skin to spinal cord and brain.
• EBV settles in memory B cells, long-lived immune cells that store the "recipe" for an antibody.
• CMV settles in cells of the myeloid lineage, the family that includes monocytes, which circulate in blood and mature into macrophages.
• HHV-6 and HHV-7 infect T cells and other tissues.
• KSHV infects B cells and the cells that line blood vessels.

Inside a latent cell, the viral DNA typically sits as a small circle called an episome, separate from the host chromosomes, and gets copied along with the cell when it divides. That is the trick behind EBV and KSHV in particular: the virus rides along as the host cell multiplies, without ever making a single virus particle.

Reactivation and why it matters

Latency is not permanent silence. Something, in some people, flips the switch back to the lytic program and the virus starts producing particles again. Triggers that doctors and researchers describe include fever, physical or emotional stress, sunlight on the skin, hormonal changes, and weakened cell-mediated immunity, the branch of the immune system run by T cells. Often no trigger is found at all.

The immune system is the main brake on reactivation, which is why herpesvirus disease clusters in people with weakened immunity: older adults, transplant recipients, and people living with untreated HIV. The brake is also why a successful immune response to the first infection is not a cure. It controls the virus; it does not remove it.

Our article on how the immune system recognizes threats covers the machinery that keeps these viruses in check, and the piece on T-cell receptors explains how the cells that do the policing identify infected cells.

HSV-1 and HSV-2: cold sores and genital herpes

The two herpes simplex viruses are close genetic cousins. The old rule of thumb, HSV-1 above the waist and HSV-2 below, has loosened, because both viruses can infect either site and HSV-1 now causes a notable share of genital infections.

WHO's most recent estimates, for 2020, put 3.8 billion people under 50 (64%) as infected with HSV-1 and about 520 million people aged 15 to 49 (13%) as infected with HSV-2 (WHO fact sheet). WHO also estimates that about 205 million people in that age group (5.3%) had at least one symptomatic episode of genital herpes. The gap between infection and symptoms matters: many people carry the virus without ever knowing it.

Feature	HSV-1	HSV-2
Global infection estimate, 2020 (WHO)	3.8 billion people under 50 (64%)	520 million people aged 15 to 49 (13%)
Typical first infection	Often childhood, through saliva	Usually adulthood, through sexual contact
Main latency site	Sensory neurons (trigeminal ganglia)	Sensory neurons (sacral ganglia)
Typical recurrent disease	Cold sores; can also affect genitals	Genital lesions; may also appear elsewhere

What an outbreak is

An outbreak is reactivation in action. The virus travels down a sensory nerve fiber to the skin, replicates in surface cells, and produces the characteristic cluster of small blisters that crust over. Because the virus returns through the same nerve each time, recurrences tend to appear in the same patch of skin.

Between outbreaks the virus can still shed from the skin without visible sores, which is a major route of transmission. WHO notes that most infected people are unaware of it, and that treatment is possible but not curative.

How antivirals work

Acyclovir, valacyclovir, and famciclovir are the standard drugs. They are built around a clever selectivity: acyclovir looks like guanosine, one of the four DNA building blocks, but it needs an enzyme called thymidine kinase to activate it, and the virus supplies that enzyme while healthy cells largely do not. Once activated, the drug is slipped into the growing viral DNA, and because it lacks the chemical hook needed to add the next building block, the strand stops growing (Huang et al., PNAS 1999, background on the mechanism, via PubMed Central).

This is why the drugs shorten outbreaks and cut viral shedding but cannot reach latent virus. A drug that blocks DNA copying does nothing to a genome that is not being copied. WHO states that treatment for recurrent episodes works best when started within 48 hours of symptoms, and that daily suppressive therapy can reduce how often symptoms occur and may lower transmission risk.

Serious cases

Most herpes simplex infections are a nuisance. Two situations are different. WHO puts neonatal herpes at roughly 10 per 100,000 births globally, with the highest risk when a mother first acquires HSV late in pregnancy, and describes it as capable of causing lasting neurologic disability or death. WHO also reports that HSV-2 infection raises the risk of acquiring HIV about threefold. Our HIV explainer covers why genital sores and the immune cells they attract create an easier path for HIV.

VZV: chickenpox first, shingles later

Varicella-zoster virus has the most visible two-act life story in the family. The first act is chickenpox, the second is shingles, and the same virus writes both.

The Centers for Disease Control and Prevention (CDC) says up to 90% of non-immune close contacts become infected, and a person is contagious from one to two days before the rash appears until every blister has crusted over (CDC chickenpox overview). Chickenpox can be dangerous in pregnancy, in infants, in adults, and in people with weakened immunity. U.S. cases have fallen more than 97% since the vaccination program began, according to the same page.

Act two: shingles

After chickenpox clears, the virus stays dormant in nerve cells. Years later it can reactivate in one nerve and travel along its fiber to the skin, producing a painful, blistering, band-shaped rash on one side of the body. The band follows a dermatome, the strip of skin wired to a single spinal nerve, which explains why shingles rarely crosses the midline.

The CDC lists older age, immune-weakening conditions such as leukemia, lymphoma, and HIV, and immune-suppressing drugs such as steroids and transplant medicines as risk factors (CDC shingles overview). The most common complication is postherpetic neuralgia (PHN), long-lasting nerve pain after the rash has healed. Antivirals shorten the illness and work best when started as soon as the rash appears.

Vaccines for both acts

VZV is the one herpesvirus with widely used vaccines. The chickenpox vaccine is given in two doses. For shingles, the CDC recommends the recombinant vaccine Shingrix in two doses, two to six months apart, for adults 50 and older, and for adults 19 and older with weakened immune systems (CDC shingles vaccine page).

Group	Shingrix effectiveness against shingles (CDC)
Healthy adults 50 to 69	97%
Healthy adults 70 and older	91%
Adults with weakened immune systems	68% to 91%, depending on the condition

The CDC also reports 91% effectiveness against postherpetic neuralgia in adults 50 and older (89% in those 70 and older), and states that about one in three people in the United States will have shingles in their lifetime. For the full clinical picture, including how doctors tell shingles from other rashes, read our deeper article on shingles and the varicella-zoster virus.

EBV: from mono to multiple sclerosis

Epstein-Barr virus is one of the most successful human viruses. CDC calls it one of the most common human viruses, and a Harvard T.H. Chan School of Public Health summary puts infection at about 95% of adults. Most people catch it in childhood without noticing.

It spreads mainly through saliva, which earned infectious mononucleosis its nickname, the kissing disease. When the first infection happens in the teens or twenties, it often causes mono: fatigue, fever, sore throat, swollen neck lymph nodes, and sometimes an enlarged spleen or liver. CDC says teens and adults usually recover in two to four weeks, although fatigue can linger for weeks or months (CDC EBV overview). There is no vaccine against EBV.

A virus that rewires the cells it lives in

EBV is unusual because its latent form does not just sit still; it nudges its host cell to survive and divide. A B cell carrying EBV can be pushed into a growth-friendly state, which in a healthy person is kept in check by T cells. In people with weakened T-cell control, such as transplant recipients on immunosuppressive drugs, that same growth push can turn into disease.

EBV is linked to several cancers, including Burkitt lymphoma, some Hodgkin lymphomas, and nasopharyngeal carcinoma, a cancer of the upper throat. The virus is a contributing factor, not a sufficient cause: the overwhelming majority of infected people never develop any of them. Our article on what causes cancer explains why cancer usually needs more than one hit.

The multiple sclerosis finding

The most discussed EBV result of recent years came from a study published in Science on January 13, 2022. Researchers led by Alberto Ascherio at Harvard followed more than 10 million young adults on active duty in the U.S. military, 955 of whom were diagnosed with multiple sclerosis (MS) during service. The risk of MS rose 32-fold after EBV infection and did not rise after infection with other viruses, and blood levels of neurofilament light chain, a marker of nerve damage, rose only after EBV infection (Harvard T.H. Chan School of Public Health summary).

The study authors describe EBV as the likely leading cause of MS, not a proven sole cause. The numbers explain the caution: nearly every adult carries EBV, and MS is rare, so EBV alone cannot be enough. MS symptoms also appear roughly a decade after infection, and early signs may go unnoticed. The lead author suggests that an EBV vaccine or EBV-targeted antiviral drugs could eventually help prevent or treat MS, and he frames that as a possibility, not a result.

CMV: the virus most people never notice

Cytomegalovirus (the name means "big cell virus," after the swollen look of infected cells under a microscope) is very widespread worldwide. A 2022 systematic review in BMC Public Health reported that among women of reproductive age, global seroprevalence, meaning the share of people with antibodies showing past infection, was about 86%. It was highest in the WHO Eastern Mediterranean region (92%) and lowest in the WHO European region (70%) (Fowler et al., 2022, via PubMed Central).

In healthy children and adults, infection is usually silent or mimics a mild flu-like illness. The virus spreads through saliva, urine, breast milk, blood, sexual contact, and transplanted organs, and young children in group care are an efficient source of household infection.

Where CMV causes real harm

Two groups carry most of the risk. The first is people with severely weakened immune systems, such as organ and stem cell transplant recipients and people with advanced untreated HIV, in whom reactivation can inflame the lungs, gut, or retina. Antiviral drugs including ganciclovir and valganciclovir are used for treatment, and newer drugs such as letermovir are used to prevent CMV disease in transplant settings.

The second group is babies infected before birth. The CDC reports that about one in 200 babies is born with congenital CMV, and about one in five of those babies has birth defects or long-term health problems (CDC congenital CMV page). Hearing loss is common among them, and it can appear after a baby has passed the newborn hearing screening, so regular hearing checks are recommended. The CDC also notes that by age five, about one in three children has been infected.

Our dedicated article on cytomegalovirus goes further into diagnosis, congenital screening, and treatment.

HHV-6 and HHV-7: roseola and a genetic oddity

HHV-6 and HHV-7 are the two roseolaviruses. They cause roseola, sometimes called sixth disease, an illness of infancy and early childhood typically marked by a few days of high fever followed by a faint rash as the fever drops. Most infections are mild, and most people are infected in early life.

Like their cousins, they persist afterward. In people with weak T-cell immunity, reactivation of HHV-6 can cause serious illness, including inflammation of the brain, particularly after stem cell transplantation. Other proposed links, for example to multiple sclerosis or chronic fatigue, remain debated and unproven.

When the virus is part of your chromosomes

HHV-6 has a property that is rare among human herpesviruses: it can integrate its whole genome into the telomere, the protective cap at the end of a chromosome. If this happens in an egg or sperm cell, the person born from it carries a copy of the virus in every nucleated cell of their body, a condition called chromosomally integrated HHV-6 (ciHHV-6). Because the viral DNA sits in the germline, it is inherited the way eye color is, with a 50% chance of passing to each child.

A review available through PubMed Central reports that roughly 1% of cord blood and healthy blood donor samples from the United States and United Kingdom are positive (ciHHV-6 review, PMC). The practical problem is diagnostic: carriers show very high viral loads in whole blood, which can be mistaken for active infection and trigger unnecessary antiviral treatment. The review notes that no disease has been conclusively tied to ciHHV-6, so routine screening is not recommended and antivirals are not advised for symptom-free carriers.

HHV-8 (KSHV): the cancer virus of the family

Kaposi's sarcoma-associated herpesvirus was identified in connection with Kaposi's sarcoma, a tumor of the cells lining blood and lymph vessels. The virus is also linked to primary effusion lymphoma and multicentric Castleman disease, rare conditions of immune cells. In people with healthy immunity, infection usually stays quiet; disease appears mostly after immune suppression, which is why Kaposi's sarcoma became so visible during the early years of the AIDS epidemic.

How common the virus is depends heavily on geography. Infection is much more common in parts of sub-Saharan Africa than in the United States and Europe, and the highest rates are in the East and Central African region sometimes called the "KS belt". In high-prevalence regions, the virus is thought to be mostly acquired in childhood from family members, and saliva is a suspected but not confirmed route. Sexual transmission is thought to matter more where infection is less common.

Why are herpes vaccines and cures so hard to build?

Seen from the immune system's side, latency is a masterclass in staying unnoticed. A vaccine usually trains the body to spot a virus when it shows itself. A herpesvirus in latency shows almost nothing, and the reservoir lives inside cells the immune system cannot afford to destroy, such as neurons, which do not regenerate.

Herpesviruses also carry large genomes with many genes devoted to manipulating the host: blocking antigen presentation, imitating host signaling molecules, and slowing the death of infected cells. They do not need to win the arms race; they need only to survive in it. Our article on how vaccines train memory B cells shows what a vaccine normally has to achieve, and it makes plain why a virus that hides inside memory B cells, as EBV does, is such a hard target.

What exists, and what does not

The picture below is current as best this article can verify. The varicella and shingles vaccines work, and CDC confirms there is no vaccine against EBV. Candidate vaccines for HSV, CMV, and EBV have been under development for years, but no vaccine for them is in routine use. On the cure side, researchers are exploring several ideas: therapeutic vaccines that boost T-cell control, drugs that force latent virus out of hiding so it can be treated, and gene-editing tools aimed at viral genomes. These remain research-stage approaches, not treatments.

Persistent virus	Where it hides	Curable today?	Routine vaccine?
Herpesviruses	Neurons, B cells, myeloid cells	No	Only VZV (chickenpox, shingles)
HIV	CD4 T cells (integrated DNA)	No	No
Hepatitis B	Liver cells	Rarely	Yes
Hepatitis C	Liver cells	Yes, with antiviral drugs	No
HPV	Basal skin and mucosal cells	Immune system clears most infections	Yes

For parallel stories of viruses that persist, see our explainers on HIV and HPV for the vaccine success, and hepatitis B and C for the liver viruses that can now be cured or prevented.

What people get wrong about herpes

Three misunderstandings come up again and again, and each leads to either unnecessary fear or false comfort.

"Herpes means genital herpes." Herpes simplex is only two of the nine, and chickenpox, mono, and roseola are herpesvirus diseases too. Cold sores are herpes, and most people with HSV-1 got it in childhood from nothing more dramatic than family contact.

"No symptoms means no virus, and no virus means no transmission." The WHO estimates make the point: 520 million people have HSV-2, but far fewer have ever had a recognized episode. Shedding without sores is real, which is why suppressive therapy and honest conversations with partners both matter. This is general information; individual decisions belong with a clinician.

"Antibodies mean you are protected." For many viruses, antibodies signal immunity. For herpesviruses, antibodies are more often a marker of lifelong infection. A positive CMV or EBV antibody test means the virus is present in the body, and it does not mean a second infection is impossible.

The takeaway

The herpesvirus family succeeded by making a different bargain from most viruses. Rather than win quickly and be cleared, each of the nine trades speed for staying power, hiding in a cell type that fits its biology and reappearing when the immune brake loosens. That one strategy explains why a cold sore returns to the same lip, why shingles decades after chickenpox, why CMV matters for newborns and transplant patients, and why EBV has now been tied to MS. It also explains why drugs that block viral copying help during outbreaks but leave the hidden reservoir untouched, and why only the VZV vaccines have broken through.

Frequently asked questions

Q: Can oral herpes spread to the genitals? A: Yes. HSV-1 can infect the genitals through oral-genital contact, and WHO notes the virus is no longer confined to the mouth. Whether lesions appear varies widely from person to person.

Q: Is a cold sore contagious when there is no visible sore? A: It can be. Herpes simplex shedding can happen without symptoms, which WHO identifies as a key reason the virus spreads so widely. The risk is highest while blisters are present.

Q: Why does shingles affect only one side of the body? A: The virus reactivates in a single nerve root and travels along that nerve to the skin it serves. The CDC describes the rash as usually appearing on one side of the body, following the territory of the affected nerve.

Q: Should adults get the shingles vaccine? A: The CDC recommends two doses of Shingrix for adults 50 and older, and for adults 19 and older with weakened immune systems. Your own clinician can advise on timing and eligibility.

Q: Is Epstein-Barr virus the cause of multiple sclerosis? A: The 2022 Science study found a 32-fold higher risk of MS after EBV infection and no increase after other viruses, and its authors call EBV the likely leading cause. Because most adults carry EBV and few develop MS, EBV is probably necessary but not sufficient.

Q: Can pregnant women do anything about CMV? A: The CDC describes congenital CMV as affecting about one in 200 babies. General hygiene measures, such as washing hands after handling a young child's saliva, diapers, or toys, reduce exposure, and a clinician can discuss testing options. There is no CMV vaccine in routine use.

Q: Is there a cure for herpes on the horizon? A: No cure exists today. Antivirals control outbreaks but do not remove latent virus, and approaches such as therapeutic vaccines and gene editing are still in the research stage.

Sources

• World Health Organization. Herpes simplex virus fact sheet (2020 estimates).
• Centers for Disease Control and Prevention. About shingles, Shingles vaccination, About chickenpox, Epstein-Barr virus, and Congenital CMV infection.
• Harvard T.H. Chan School of Public Health. Summary of Bjornevik et al., Science, January 13, 2022.
• Fowler K, et al. A systematic literature review of the global seroprevalence of cytomegalovirus. BMC Public Health, 2022, via PubMed Central.
• Chromosomally integrated human herpesvirus 6 review, via PubMed Central.
• Huang L, et al. Enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir. PNAS, 1999, via PubMed Central.
• International Committee on Taxonomy of Viruses. Herpesviridae chapter.

---

Read next:

• Dengue Virus Explained — Why It's Spreading and How It Works
• Ebola Virus Explained — How It Works and Why It's So Lethal
• H5N1 Bird Flu Explained — How the Virus Works in 2026